| Name | Sarcosine |
| Description | Sarcosine (Methylglycine) is a competitive inhibitor of the type I glycine transporter (GlyT1) and an N-methyl-D-aspartate receptor (NMDAR) co-agonist. |
| Cell Research | Immediately after the cells grow to 50-60% confluence, the cultivation medium is replaced by fresh medium to synchronise cell growth. Cells are cultivated for 24 h under these conditions. Subsequently, the culture medium is supplemented with sarcosine (N-methylglycine) diluted to a final concentration 10, 150, 250, 500, 1,000 and 1,500 μM. Treatment is carried out for 0, 6, 12, 24 and 72 h, and samples are collected at these strictly defined time points.(Only for Reference) |
| In vitro | Sarcosine is a GlyR agonist in addition to being a GlyT1 inhibitor and NMDAR co-agonist, but it is less potent than glycine as a GlyR agonist and is not a full agonist[1]. The viability of the sarcosine-treated cells is significantly reduced[4]. |
| In vivo | Sarcosine has weak anticonvulsant properties[2]. It ameliorates (prepulse inhibition)PPI deficits in mGluR5 knockout mice[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : Insoluble
H2O : 10 mM
|
| Keywords | inhibit | dysfunction | schizophrenia | Endogenous Metabolite | Inhibitor | Sarcosine | cognitive | depression | GlyT | Glycine transporters |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Natural Product Library | Drug Repurposing Compound Library | Natural Product Library for HTS | Human Endogenous Metabolite Library |
United States
